Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Date publication

janvier 2024

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38190578

Résumé

Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B).

Référence

J Clin Oncol. 2024 01 8;:JCO2300458